Hypericum perforatum: Pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 643-655

  Russo, Emilio ^a,b   Scicchitano, Francesca ^a,b   Whalley, Benjamin J ^c   Mazzitello, Carmela ^a,b   Ciriaco, Miriam ^a,b   Esposito, Stefania ^a,b   Patanè, Marinella ^a,b   Upton, Roy ^d   Pugliese, Michela ^e   Chimirri, Serafina ^a,b   Mammì, Maria ^a,b   Palleria, Caterina ^a,b   De Sarro, Giovambattista ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

^c UNIVERSITY OF READING   (United Kingdom)

^d American Herbal Pharmacopoeia   (United States)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

cytochrome P450; drugs; Hypericum perforatum; interaction; P glycoprotein; St. John's wort

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; DESOGESTREL; DEXAMETHASONE; DIGOXIN; ETHINYLESTRADIOL; FEXOFENADINE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; LOPERAMIDE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PANTOPRAZOLE; PHENPROCOUMON; PSEUDOHYPERICIN; SIMVASTATIN; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ALLERGIC REACTION; ANTIBACTERIAL ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHENIA; COLIC; CONFUSION; DEPRESSION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; LETHARGY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHOTOALLERGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PHYTOCHEMISTRY; RASH; RESTLESSNESS; REVIEW; SEROTONIN SYNDROME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

CLUSIACEAE; HYPERICUM PERFORATUM;

CYTOCHROME P450; DRUGS; HYPERICUM PERFORATUM; INTERACTION; P-GLYCOPROTEIN; ST. JOHN'S WORT;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; DEPRESSION; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; PERYLENE; PHLOROGLUCINOL; PLANT EXTRACTS; PLANTS, MEDICINAL; TERPENES;

EID: 84899494066     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5050     Document Type: Review

References (171)

1. Alscher DM, Klotz U,. 2003. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transpl Int 16: 543-544.
2. Andrén L, Andreasson A, Eggertsen R,. 2007. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 63: 913-916.
3. Beijamini V, Andreatini R,. 2003. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol Res 48: 199-207.
4. Bell EC, Ravis WR, Chan HM, Lin YJ,. 2007a. Lack of pharmacokinetic interaction between St. John's wort and prednisone. Ann Pharmacother 41: 1819-1824.
5. Bell EC, Ravis WR, Lloyd KB, Stokes TJ,. 2007b. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 41: 229-234.
6. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR,. 2004. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103: 698-709.
7. Bennett DA, Phun L Jr, Polk JF, Voglino SA, Zlotnik V, Raffa RB,. 1998. Neuropharmacology of St. John's wort (Hypericum). Ann Pharmacother 32: 1201-1208.
8. Bent S,. 2008. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 23: 854-859.
9. Bianchi A, Adamoli R, Durante A, Saibene A,. 1997. Piante Medicinali e AIDS. Ed. Tecniche Nuove: Milan.
10. Biber A, Fischer H, Römer A, Chatterjee SS,. 1998. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31: 36-43.
11. Bladt S, Wagner H,. 1994. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol 7: 57-59.
12. Bombardelli E, Morazzoni P,. 1995. Hypericum perforatum. Fitoterapia 66: 43-68.
13. Bon S, Hartmann K, Kubn M,. 1999. Johanniskraut: Enzyminduktor Ein? Schweitzer Apothekerzeitung 16: 535-536.
14. Bonetto N, Santelli L, Battistin L, Cagnin A,. 2007. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and Hypericum. Cephalalgia 27: 1421-1423.
15. Borrelli F, Izzo AA,. 2009. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 11: 710-727.
16. Bove GM,. 1998. Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 352: 1121-1122.
17. Boyer EW, Shannon M,. 2005. The serotonin syndrome. N Engl J Med 352: 1112-1120.
18. Brochmoller J, Rheum T, Bauer S, Kerb R, Hubner WD, Roots I,. 1997. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30: 94-101.
19. Brondz I, Greibrokk T, Groth PA, Aasen AJ,. 1982. The relative stereochemistry of hyperforin-an antibiotic from Hypericum perforatum L. Tetrahehedron Lett 23: 1299-1300.
20. Butterweck V, Schmidt M,. 2007. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 157: 356-361.
21. Butterweck V,. 2003. Mechanism of action of St John's wort in depression: what is known? CNS Drugs 17: 539-562.
22. Caccia S, Gobbi M,. 2009. St. John's wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects. Curr Drug Metabolism 10: 1055-1065.
23. Can OD, Ozkay UD,. 2012. Effects of Hypericum montbretti extract on the central nervous system and involvement of GABA (A)/benzodiazepine receptors in its pharmacological activity. Phytother Res 26: 1695-1700.
24. Can ÖD, Öztürk Y, Demir Özkay Ü,. 2009. A natural antidepressant Hypericum perforatum L.: review. Turk Klinikleri J Med Sci 29: 708-715.
25. Can ÖD, Öztürk Y, Öztürk N, et al,. 2011. Effects of treatment with St. John's wort on blood glucose levels and pain perceptions of streptozotocin-diabetic rats. Fitoterapia 82: 576-584.
26. Capasso F, Gaginella TS, Grandolini G, Izzo AA,. 2003. Phytotherapy: A Quick Reference to Herbal Medicine. Springer Verlag: Berlin.
27. Caraci F, Crupi R, Drago F, Spina E,. 2011. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and Hypericum extract. Curr Drug Metabol 12: 570-577. Review.
28. Cauffield JS,. 2000. The psychosocial aspects of complementary and alternative medicine. Pharmacotherapy 20 (11): 1289-1294.
29. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE,. 1998a. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 63: 499-510.
30. Chatterjee SS, Noldner M, Koch E, Erdelmeier C,. 1998b. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31: 7-15.
31. Chen XW, Serag ES, Sneed KB, et al,. 2011. Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Mel Chem 8: 4836-4850. Review.
32. Chen XW, Sneed KB, Pan SY, et al,. 2012. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metabol 13: 640-651.
33. Cheung CK, Wyman JF, Halcon LL,. 2007. Use of complementary and alternative therapies in community-dwelling older adults. J Altern Complement Med 13 (9): 997-1006.
34. Cookson J,. Side-effects of antidepressants. 1993. Br J Psychiatry 163: 20-24.
35. Crupi R, Mazzon E, Marino A, et al,. 2011. Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement Altern Med 11: 7.
36. Dasgupta A, Tso G, Szelei-Stevens K,. 2006. St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. J Clin Lab Anal 20: 62-67.
37. De Marchis GM, Bürgi S, Kientsch U, Honegger UE,. 2006. Vitamin E reduces antidepressant-related beta-adrenoceptor down-regulation in cultured cells. Comparable effects on St. John's wort and tricyclic antidepressant treatment. Planta Med 72: 1436-1437.
38. De Smet PA, Nolen WA,. 1996. St John's wort as an antidepressant. BMJ 313: 241-242.
39. De Smet PA,. 2007. Clinical risk management of herb-drug interactions. Br J Clin Pharmacol 63: 258-267.
40. Degar S, Prince AM, Pascual D, et al,. 1992. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alteration of p24 and block in uncoating. AIDS Res Hum Retrovirus 8: 1929-1936.
41. Di YM, Li CG, Xue CC, Zhou SF,. 2008. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Design 14: 1723-1742.
42. Doffoel-Hantz V, Boulitrop-Morvan C, Sparsa A, Bonnetblanc JM, Dalac S, Bédane C,. 2009. Photosensitivity associated with selective serotonin reuptake inhibitors. Clin Exp Dermatol 34: 763-765.
43. Dostalek M, Pistovcakova J, Jurica J, et al,. 2005. Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sci 78: 239-244.
44. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB,. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73: 41-50.
45. Dugoua JJ, Mills E, Perri D, Koren G,. 2006. Safety and efficacy of St. John's wort (Hypericum) during pregnancy and lactation. Can J Clin Pharmacol 13: 268-276. Review.
46. Dürr D, Stieger B, Kullak-Ublick GA, et al,. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604.
47. Eggertsen R, Andreasson A, Andrén L,. 2007. Effects of treatment with a commercially available St John's wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care 25: 154-159.
48. Eisenberg DM, Davis RB, Ettner SL, et al,. 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575.
49. Ernst E,. 1998. Harmless herbs? A review of the recent literature. Am J Med 104: 170-178. Review.
50. Evans RW,. 2008. Triptans and serotonin syndrome. Cephalalgia 28: 573-574.
51. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ,. 2004. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76: 323-329.
52. Fugh-Berman A, Kronenberg F,. 2003. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol 17: 137-152. Review.
53. Gaind KN, Ganjoo TN,. 1959. Antibacterial principle of Hypericum perforatum Linn. Indian J Pharm 21: 172.
54. Gastpar M, Singer A, Zeller K,. 2006. Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 39: 66-75.
55. Gibbons S, Ohlendorf B, Johnsen I,. 2002. The genus Hypericum-a valuable resource of anti-staphylococcal leads. Fitoterapia 73: 300-304.
56. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J,. 1997. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract. Hautarzt 48: 249-252.
57. Gottesman MM, Pastan I, Ambudkar SV,. 1996. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617.
58. Gregoretti B, Stebel M, Candussio L, Crivellato E, Bartoli F, Decorti G,. 2004. Toxicity of Hypericum perforatum (St. John's wort) administered during pregnancy and lactation in rats. Toxicol Appl Pharmacol 200: 201-205.
59. Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC,. 2010. Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. Curr Med Chem 17: 391-406.
60. Gröning R, Breitkreutz J, Müller RS,. 2003. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. Eur J Pharm Biopharm 56: 231-236.
61. Gurley BJ, Gardner SF, Hubbard MA, et al,. 2005. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22: 525-539.
62. Hall SD, Wang Z, Huang SM, et al,. 2003. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 74: 525-535.
63. He SM, Sneed KB, Chen XW, Cao C, Zhou SF,. 2012. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metabol 13: 640-651.
64. Hemeryck A, Belpaire FM,. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metabl 3: 13-37. Review.
65. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P,. 2002. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54: 349-356. Review.
66. Hennessy M, Kelleher D, Spiers JP, et al,. 2002. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53: 75-82.
67. Hoffmann J, Kühl ED,. 1979. Therapy of depressive states with hypericin. ZFA (Stuttgart) 55: 776-782.
68. Hojo Y, Echizenyam M, Ohkubo T, Shimizu T,. 2011. Drug interaction between St John's wort and zolpidem in healthy subjects. J Clin Pharm Ther 36: 711-715.
69. Holtzman CW, Wiggins BS, Spinler SA,. 2006. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26: 1601-1607.
70. Hu Z, Yang X, Ho PC, et al,. 2005. Herb-drug interactions: a literature review. Drugs 65: 1239-1282.
71. Hypericum Depression Trial Study Group. 2002. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 287: 1807-1814.
72. Imai H, Kotegawa T, Tsutsumi K, et al,. 2008. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 65: 701-707.
73. Izzo A, Ernst E,. 2009. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69: 1777-1798.
74. Izzo AA,. 2004. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42: 139-148.
75. Izzo AA,. 2012. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 21: 404-428.
76. Jiang X, Williams KM, Liauw WS, et al,. 2004. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57: 592-599.
77. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I,. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338-345.
78. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M,. 2006. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 23: 4-14.
79. Kasper S, Caraci F, Forti B, Drago F, Aguglia E,. 2010. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol 20: 747-765.
80. Kasper S, Volz HP, Moller HJ, Dienel A, Kieser M,. 2008. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression-a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol 18: 803-813.
81. Khawaja IS, Marotta RF, Lippmann S,. 1999. Herbal medicines as a factor in delirium. Psychiatr Serv 50: 969-970.
82. Khosa RL, Bhatia N,. 1982. Antifungal effect of Hypericum perforatum. J Sci Res Pt Med 3: 49-50.
83. Kim HL, Streltzer J, Goebert D,. 1999. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187: 532-538.
84. Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, Ritsick M,. 2011. Medical attributes of St. John's wort (Hypericum perforatum). In Herbal Medicine: Biomolecular and Clinical Aspects, (2nd edn), Benzie IFF, Wachtel-Galor S, (eds). CRC Press: Boca Raton, FL; Chapter 11.
85. Lantz MS, Buchalter E, Giambanco V,. 1999. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol Spring 12: 7-10.
86. Lecrubier Y, Clerc G, Didi R, Kieser M,. 2002. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 159: 1361-1366.
87. Lee A, Minhas R, Matsuda N, Lam M, Ito S,. 2003. The safety of St. John's wort (Hypericum perforatum) during breastfeeding. J Clin Psychiatry 64: 966-968.
88. Linde K, Berner MM, Kriston L,. 2008. St John's wort for major depression. Cochrane Database Syst Rev 4: CD000448. Review.
89. Linde K, Knüppel L,. 2005. Large-scale observational studies of Hypericum extracts in patients with depressive disorders-a systematic review. Phytomedicine 12: 148-157. Review.
90. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D,. 1996. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 313: 253-258.
91. Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I,. 2003. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18: 819-822.
92. Markowitz JS, Donovan JL, DeVane CL, et al,. 2003. Effects of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290: 1500-1504.
93. Mathew NT, Tietjen GE, Lucker C,. 1996. Serotonin syndrome complicating pharmacotherapy. Cephalalgia 16: 323.
94. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A,. 2002. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94: 1247-1249.
95. Meruelo D, Lavie G, Lavie D,. 1988. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A 85: 5230-5234.
96. Montgomery SA, Hübner WD, Grigoleit HG,. 2000. Efficacy and tolerability of St John's wort extract compared with placebo in patients with a mild to moderate depressive disorder. Phytomedicine 7: 107.
97. Moretti ME, Maxson A, Hanna F, Koren G,. 2009. Evaluating the safety of St. John's wort in human pregnancy. Reproduc Toxicol 28: 96-99.
98. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S,. 2004. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 44: 95-101.
99. Moses EL, Mallinger AG,. 2000. St. John's wort: three cases of possible mania induction. J Clin Psychopharmacol 20: 115-117.
100. Mueller SC, Uehleke B, Woehling H, et al,. 2004. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75: 546-557.
101. Mueller SC, Majcher-Peszynska J, Mundkowski RG, et al,. 2009. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 65: 81-87.
102. Müller WE,. 2003. Current St. John's wort research from mode of action to clinical efficacy. Phamacol Res 47: 101-109.
103. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL,. 2005. Interaction of St. John's wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71: 402-408.
104. Nahrstedt A, Butterweck V,. 1997. Biologically active and other chemical constituents of the herb of Hypericum perforatum. Pharmacopsychiatry 30: 129-134.
105. Nangia M, Syed W, Doraiswamy PM,. 2000. Efficacy and safety of St. John's wort for the treatment of major depression. Public Health Nutr 3: 487-494. Review.
106. Nebel A, Schneider BJ, Baker RK, Kroll DJ,. 1999. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 33: 502.
107. Negrash AK, Pochinok PY,. 1972. Comparative study of chemotherapeutic and pharmacological properties of antimicrobial preparations from common St. John's wort. Fitonotsidy Mater, Soveshch 6: 198-200.
108. Nieminen TH, Hagelberg NM, Saari TI, et al,. 2010. St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 14: 854-859.
109. Nierenberg AA, Burt T, Matthews J, Weiss AP,. 1999. Mania associated with St. John's wort. Biol Psychiatry 46: 1707-1708.
110. Ott M, Huls M, Cornelius MG, Fricker G,. 2010. St. John's wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm Res 27: 811-822.
111. Öztürk N, Korkmaz S, Öztürk Y,. 2006. Wound-healing activity of St. John's wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. J Ethnopharmacol 111: 33-39.
112. Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ,. 2001. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 134: 1601-1608.
113. Rahimi R, Abdollahi M,. 2012. An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol 8: 691-708.
114. Rahimi R, Nikfar S, Abdollahi M,. 2009. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Progr Neuropsychopharmacol Biol Psychiatry 33: 118-127.
115. Rao SG, Udupa AL, Udupa SL, Rao PGM, Rao G, Kulkarni DR,. 1991. Calendula and Hypericum: two homeopathic drugs promoting wound healing in rats. Fitoterapia 62: 508-510.
116. Rayburn WF, Christensen HD, Gonzalez CL,. 2000. Effect of antenatal exposure to Saint John's wort (Hypericum) on neurobehavior of developing mice. Am J Obstet Gyneco 183: 1225-1231.
117. Rayburn WF, Gonzalez CL, Christensen HD, Harkins TL, Kupiec TC,. 2001a. Impact of Hypericum (St.-John's-wort) given prenatally on cognition of mice offspring. Neurotoxicol Teratol 23: 629-637.
118. Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD,. 2001b. Effect of prenatally administered Hypericum (St John's wort) on growth and physical maturation of mouse offspring. Am J Obstet Gynecol 184: 191-195.
119. Rengelshausen J, Banfield M, Riedel KD, et al,. 2005. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78: 25-33.
120. Rodríguez-Landa JF, Contreras CM,. 2003. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10: 688-699. Review
121. Rosenberg L, Bégaud B, Bergman U, et al,. 1996. What are the risks of third-generation oral contraceptives? Are third-generation oral contraceptives safe? Hum Reprod 11: 687-688. Review.
122. Saddiqe Z, Naeem I, Maimoona A,. 2010. A review of the antibacterial activity of Hypericum perforatum L. J Ethnopharmacol 131: 511-521.
123. Šaljic̈ J,. 1975. Ointment for treatment of burns. Ger Offen 83: 197797.
124. Saroglou V, Marin PD, Rančic̈ A, Veljic̈ M, Skaltsa H,. 2007. Composition and antimicrobial activity of the essential oil of six Hypericum species from Serbia. Biochem Syst Ecol 35: 146-152.
125. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389.
126. Schempp CM, Winghofer B, Langheinrich M, Schopf E, Simon JC,. 1999. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of Hypericum perforatum L. extract. Skin Pharmacol Appl Skin Physiol 12: 299-304.
127. Schrader E, Meier B, Brattström A,. 1998. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13: 163-169.
128. Schrader E,. 2000. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61-68.
129. Schulz HU, Schürer M, Bässler D, Weiser D,. 2006. Investigation of the effect on photosensitivity following multiple oral dosing of two different Hypericum extracts in healthy men. Arzneimittelforschung 56: 212-221.
130. Schulz V, Johne A,. 2005. Side effects and drug interactions. In Milestones in Drug Therapy: St. John's Wort and Its Active Principles in Depression and Anxiety, Müller WE, (ed.). Birkhaüser-Verlag: Basel; 145-160.
131. Schulz V,. 2006. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 13: 199-204.
132. Schwartz RH, Rodrigues WJ,. 1991. Toxic delirium possibly caused by loperamide. J Pediatr 118: 656-657.
133. Schwarz UI, Hanso H, Oertel R, et al,. 2007. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81: 669-678.
134. Shakirova KK, Garagulia dC, Khazanovich RL,. 1970. Antimicrobic properties of some species of St. John's wort cultivated in Uzbekistan. Mikrobiol Zh 32: 494-497.
135. Shelton RC, Keller MB, Gelenberg A, et al,. 2001. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285: 1978-1986.
136. Shimizu K, Nakamura M, Isse K, Nathan PJ,. 2004. First-episode psychosis after taking an extract of Hypericum perforatum (St John's wort). Hum Psychopharmacol 19: 275-276.
137. Shitara Y, Sugiyama Y,. 2006. Pharmacokinetic and pharmacodynamics alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme function. Pharmacol Ther 112: 71-105.
138. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ,. 2004. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24: 1508-1514.
139. Staffeldt B, Kerb R, Brockmöller J, Ploch M, Roots I,. 1994. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 7: 47-53.
140. Stevinson C, Ernst E,. 2004. Can St. John's wort trigger psychoses? Int J Clin Pharmacol Ther 42 (9): 473-80.
141. Sugimoto KI, Ohmori M, Tsuruoka S, et al,. 2001. Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518-524.
142. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H,. 1984. Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272-274.
143. Szegedi A, Kohnen R, Dienel A, Kieser M,. 2005. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 330: 503.
144. Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T,. 1989. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophysl Res Commun 165: 1207-1212.
145. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H,. 2004. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 75: 298-309.
146. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC,. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84: 7735-7738.
147. Thomas C, MacGill RS, Miller GC, Pardini RS,. 1992a. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase. Photochem Photobiol 55: 47-53.
148. Thomas C, MacGill RS, Neill P, Pardini RS,. 1992b. The in vitro and in vivo photoinduced antineoplastic activity of hypericin [meeting abstract]. Proc Annu Meet Am Assoc Cancer Res 33: 2989.
149. Uebelhack R, Gruenwald J, Graubaum HJ, Busch R,. 2004. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther 21: 265-275.
150. Upton R,. 1997. St. John's wort (Hypericum perforatum). American Herbal Pharmacopoeia (AHP). In HerbalGram 40. American Herbal Pharmacopoeia: Santa Cruz; 132.
151. Van Strater AC, Bogers JP,. 2012. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol 27: 121-124.
152. Vandebogaerde A, de Witte P,. 1995. Antineoplastic properties of photosensitized hypericin (meeting abstract). Anticancer Res 15: 1757-1758.
153. Wacher VJ, Salphati L, Benet LZ,. 1996. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 20: 99-112.
154. Wang LS, Zhu B, Abd El-Aty AM, et al,. 2004. The influence of St John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 44: 577-581.
155. Wang XD, Li JL, Lu Y, et al,. 2007. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical herb-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci 852: 534-544.
156. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD,. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70: 317-326.
157. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD,. 2002. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71: 414-420.
158. Watkins PB,. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27: 161-170.
159. West of Scotland Coronary Prevention Study Group. 1998. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97: 1440-1445.
160. Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A,. 2009. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 65: 541.
161. Woelk H, Burkard G, Grunwald J,. 1994. Benefits and risks of the Hypericum extract LI 160: drug-monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 7: 34-38.
162. Woelk H,. 2000. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 321: 536-539.
163. Wurglics M, Schubert-Zsilavecz M,. 2006. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45: 449-468. Review.
164. Xie R, Tan LH, Polasek EC, et al,. 2005. CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 45: 352-356.
165. Yip L, Hudson JB, Kowalik EG, Zalkow LH, Towers GHN,. 1996. Antiviral activity of a derivative of the photosensitive compound hypericin. Phytomedicine 3: 185-190.
166. Yue QY, Bergquist C, Gerdén B,. 2000. Safety of St John's wort (Hypericum perforatum). Lancet 355: 576-577.
167. Zdunic̈ G, Godevac D, Milenkovic̈ M, et al,. 2009. Evaluation of Hypericum perforatum oil extracts for an antiinflammatory and gastroprotective activity in rats. Phytother Res 23: 1559-1564.
168. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ,. 2004. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 18: 262-276.
169. Zhou SF, Lai X,. 2008. An update of clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 9: 394-409.
170. Zhou SF, Zhou ZW, Li CG, et al,. 2007. Identification of drugs that interact with herbs in drug development. Drug Discov Today 12: 664-673.
171. Zhou SF,. 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.